World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
AstraZeneca Plans to Cut 7,300 Jobs
Keywords:
AstraZeneca PLC showed a net profit decline of 8.3% in fourth quarter 2011, on sales that remained stable at $8.66 billion compared to $8.62 billion in the prior year quarter. AstraZeneca is facing competition from low cost generics and cuts in government health care spending similiar to the rest of the industry. The company has announced new job cuts of 7,300 job for 2012, which brings total job cuts to 30,000 for the last 5 years. Most of the job cuts are in the U.S. and Europe. Hiring has continued in emerging markets leaving the net job cuts over the last 5 years at 9,600. Of the 7,300 job cuts planned for 2012, 2,200 will be in R&D departments, 1,350 in manufacturing and 3,750 in sales. AstraZeneca is changing the way it will do research and development with these changes. It will close the neuroscience research laboratories in Sodertalje, Sweden and in Montreal. It will have in its place "virtual" neuroscience units, small groups of 40-50 researchers working with academic groups and scientists outside to utilize the best science in the field. This is one of the most radical changes in R&D practices among pharmaceutical companies. In marketing the approach has shifted from having full time sales people call doctors offices to using online marketing tools and telemarketers. This approach is also being adopted for emerging markets.
Astra Zeneca restructuring
12/08/2011
Grouped Articles
Astra Zeneca in Deal to Buy Pearl Therapeutics worth $1.5 Billion
New York Times 06/10/2013
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
AstraZeneca’s Shaky Bridge to Pipeline’s Promise
Wall Street Journal 11/18/2014
AstraZeneca Deals Up a Tricky 2015
Wall Street Journal 02/06/2015
AstraZeneca to Buy Actavis’s Respiratory Drug Business in U.S., Canada
Wall Street Journal 02/06/2015
AstraZeneca Needs to Set Itself Free
Wall Street Journal 01/04/2016
AstraZeneca
01/12/2007
Grouped Articles
Astra Isn't Immune to Competition
Wall Street Journal 03/22/2014
AstraZeneca’s Shaky Bridge to Pipeline’s Promise
Wall Street Journal 11/18/2014
AstraZeneca, Bristol-Myers To Team Up on 2 Drugs
Wall Street Journal 01/12/2007
Wall Street Journal 05/22/2007
AstraZeneca Wins Legal Halt Of Rival Drug
Wall Street Journal 11/21/2008
AstraZeneca, Teva Set Accord on Asthma Drug
Wall Street Journal 11/25/2008
AstraZeneca performance
02/27/2009
Grouped Articles
Astra Zeneca in Deal to Buy Pearl Therapeutics worth $1.5 Billion
New York Times 06/10/2013
For $520 Million, AstraZeneca Will Settle Case Over Marketing of a Drug
New York Times 04/26/2010
Astra Isn't Immune to Competition
Wall Street Journal 03/22/2014
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
U.S. DOJ Closes Probe Into AstraZeneca's Heart Drug Brilinta
Wall Street Journal 08/20/2014
AstraZeneca’s Shaky Bridge to Pipeline’s Promise
Wall Street Journal 11/18/2014
AstraZeneca strategies
02/27/2009
Grouped Articles
Astra Zeneca in Deal to Buy Pearl Therapeutics worth $1.5 Billion
New York Times 06/10/2013
AstraZeneca Cozies Up to Cambridge University
Wall Street Journal 10/25/2013
Astra Isn't Immune to Competition
Wall Street Journal 03/22/2014
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
AstraZeneca’s Shaky Bridge to Pipeline’s Promise
Wall Street Journal 11/18/2014
AstraZeneca Deals Up a Tricky 2015
Wall Street Journal 02/06/2015
Astra Zeneca's Brilinta blood thinner drug
07/20/2011
Grouped Articles
U.S. DOJ Closes Probe Into AstraZeneca's Heart Drug Brilinta
Wall Street Journal 08/20/2014
Brilinta, a Blood Thinner, Wins F.D.A. Approval
New York Times 07/20/2011
AstraZeneca Plans to Cut 7,300 Jobs
Wall Street Journal 02/03/2012
AstraZeneca, Bristol-Myers Deepen Diabetes Alliance
Wall Street Journal 02/01/2013
AstraZeneca management
02/27/2009
Grouped Articles
Astra Isn't Immune to Competition
Wall Street Journal 03/22/2014
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
AstraZeneca’s Shaky Bridge to Pipeline’s Promise
Wall Street Journal 11/18/2014
AstraZeneca Deals Up a Tricky 2015
Wall Street Journal 02/06/2015
AstraZeneca to Buy Actavis’s Respiratory Drug Business in U.S., Canada
Wall Street Journal 02/06/2015
AstraZeneca Needs to Set Itself Free
Wall Street Journal 01/04/2016
AstraZeneca legal settlements
02/27/2009
Grouped Articles
For $520 Million, AstraZeneca Will Settle Case Over Marketing of a Drug
New York Times 04/26/2010
U.S. DOJ Closes Probe Into AstraZeneca's Heart Drug Brilinta
Wall Street Journal 08/20/2014
AstraZeneca to Gain From Tax Deal
Wall Street Journal 03/28/2011
AstraZeneca Settles Most Seroquel Suits
New York Times 07/29/2011
Astra Cuts Sales Force in U.S. 24%
Wall Street Journal 12/08/2011
AstraZeneca Plans to Cut 7,300 Jobs
Wall Street Journal 02/03/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us